BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 10766581)

  • 1. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
    El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
    N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
    Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
    N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.
    Pierce M; Crampton S; Henry D; Heifets L; LaMarca A; Montecalvo M; Wormser GP; Jablonowski H; Jemsek J; Cynamon M; Yangco BG; Notario G; Craft JC
    N Engl J Med; 1996 Aug; 335(6):384-91. PubMed ID: 8663871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
    Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
    HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.
    Oldfield EC; Fessel WJ; Dunne MW; Dickinson G; Wallace MR; Byrne W; Chung R; Wagner KF; Paparello SF; Craig DB; Melcher G; Zajdowicz M; Williams RF; Kelly JW; Zelasky M; Heifets LB; Berman JD
    Clin Infect Dis; 1998 Mar; 26(3):611-9. PubMed ID: 9524832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.
    Nightingale SD; Cameron DW; Gordin FM; Sullam PM; Cohn DL; Chaisson RE; Eron LJ; Sparti PD; Bihari B; Kaufman DL
    N Engl J Med; 1993 Sep; 329(12):828-33. PubMed ID: 8179648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
    Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
    J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
    Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
    AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
    Lederman HM; Williams PL; Wu JW; Evans TG; Cohn SE; McCutchan JA; Koletar SL; Hafner R; Connick E; Valentine FT; McElrath MJ; Roberts NJ; Currier JS;
    J Infect Dis; 2003 Dec; 188(12):1794-803. PubMed ID: 14673757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
    Bayoumi AM; Redelmeier DA
    AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
    Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
    Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
    N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.